Dr Jonathan Milner

Dr Jonathan Milner, co-founder and currently Deputy Chairman of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK healthcare and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three technology companies to IPO on AIM. In 1998, he identified the market opportunity for supplying high-quality antibodies to support protein interaction studies and founded Abcam with David Cleevely and Professor Tony Kouzarides.

Jonathan is currently Chairman of Axol Bioscience, Cambridge Allergy Therapy Limited and PhoreMost Limited and a non-executive director of Horizon Discovery, Frontier Developments, Syndicate Room Limited and GeoSpock Limited. He also sits on the advisory boards of Desktop Genetics Ltd, Repositive Ltd, HealX Limited and Definigen Ltd. In addition, he co-founded the Milner Institute for Evolution at the University of Bath.